相关实验视频

Updated: Mar 18, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

整个蛋白质组的门德尔随机化和局部化分析确定了精神分裂症的潜在生物标志物

Jingyu Lin¹, Haiming Huang², Lin Chen¹

¹Beijing Huilongguan Hospital, Capital Medical University, Beijing, China.

Frontiers in psychiatry

|March 16, 2026

概括

这项研究使用了门德尔的随机化来确定七种与精神分裂症 (SCZ) 风险有因果关系的血蛋白. 这些发现突出了精神分裂症治疗和机理学研究的潜在新目标.

科学领域:

遗传学遗传学是一个
蛋白质组学是指蛋白质组学.
精神疾病精神疾病

背景情况:

精神分裂症 (SCZ) 是一种复杂的精神疾病,具有重要的遗传成分.
了解SCZ背后的生物学途径对于开发有效的治疗方法至关重要.

研究的目的:

研究血蛋白水平与精神分裂症风险之间的因果关系.
为了确定可能在SCZ病变发生过程中起作用的特定蛋白质.

主要方法:

使用遗传仪器对4,907种血蛋白进行全蛋白质门德尔随机化 (MR) 分析.
来自精神病基因组学联盟 (PGC) 的SCZ总结统计.
外部验证使用来自Fenland研究和英国生物银行药物蛋白质学项目 (UKB-PPP) 的cis-pQTL和来自GTEx的大脑cis-eQTL. 贝叶斯定位被用来评估共享的因果变异.

主要成果:

七种血蛋白与SCZ风险有显著关联:ADAM22,LIMA1,CTSS,FOXO3,IRF3,KLC1和MMP16.
对于LIMA1,CTSS,FOXO3,KLC1和MMP16的关联在外部数据集中部分复制.
贝叶斯定位强烈支持FOXO3,IRF3和LIMA1与SCZ的共同因果变异.
CTSS,FOXO3,IRF3和MMP16与已知的抗精神病药物点进行了相互作用.

结论:

这项研究为SCZ中特定血蛋白的因果作用提供了强有力的证据.
已识别的蛋白质代表了进一步机理学研究和精神分裂症治疗开发的有希望的候选人.

关键词:

在CTSS中,它是最重要的.门德尔的随机化生物标志物生物标志物定位化,定位化的地方.精神分裂症是一种精神分裂症.

更多相关视频

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

相关概念视频

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...